A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC

被引:18
作者
Singh, Aman P. [1 ]
Shah, Dhaval K. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 455 Kapoor Hall, Buffalo, NY 14214 USA
关键词
antibody-drug conjugates; bystander effect; cellular disposition; single-cell PK-PD model; trastuzumab-vc-MMAE; microtubule inhibitors; ANTIBODY-DRUG CONJUGATE; CANCER; TUMORS; PHARMACOKINETICS; DISPOSITION; SIMULATION; EXPRESSION; ANTIGEN; TISSUE;
D O I
10.1016/j.xphs.2019.01.034
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here, we have developed a cell-level systems PK-PD model to characterize the bystander effect of antibody-drug conjugates (ADCs). Cytotoxicity data generated following incubation of Trastuzumab-vc-MMAE in cocultures of high HER2-expressing N87 and low HER2-expressing GFP-MCF7 cells were used to build the model. Single-cell PK model for ADC was used to characterize the PK of trastuzumab-vc-MMAE and released MMAE in N87 and GFP-MCF7 cells. The 2 cell-level PK models were mechanistically integrated to mimic the coculture condition. MMAE-induced intracellular occupancy of tubulin was used to drive the efficacy of ADC, and improvement in the tubulin occupancy of GFP-MCF7 cells in the presence of N87 cells was used to drive the bystander effect of trastuzumab-vc-MMAE. The "dual" cell-level PK-PD model was able to capture the observed data reasonably well. It was found that similar and high occupancy of tubulin by MMAE was required to achieve the cytotoxic effect in each cell line. In addition, estimated model parameters suggested that similar to 60% improvement in the tubulin occupancy was required to attain half of the maximum bystander killing effect by the ADC. The presented model provides foundation for in vivo systems PK-PD model to characterize and predict the bystander effect of ADCs. (c) 2019 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2465 / 2475
页数:11
相关论文
共 37 条
[1]   MAYTANSINE BINDING TO VINBLASTINE SITES OF TUBULIN [J].
BHATTACHARYYA, B ;
WOLFF, J .
FEBS LETTERS, 1977, 75 (01) :159-162
[2]   Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival [J].
Cilliers, Cornelius ;
Menezes, Bruna ;
Nessler, Ian ;
Linderman, Jennifer ;
Thurber, Greg M. .
CANCER RESEARCH, 2018, 78 (03) :758-768
[3]   Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy [J].
Cilliers, Cornelius ;
Guo, Hans ;
Liao, Jianshan ;
Christodolu, Nikolas ;
Thurber, Greg M. .
AAPS JOURNAL, 2016, 18 (05) :1117-1130
[4]  
D'Argenio David Z, 2009, ADAPT 5 USERS GUIDE
[5]   Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect [J].
Golfier, Sven ;
Kopitz, Charlotte ;
Kahnert, Antje ;
Heisler, Iring ;
Schatz, Christoph A. ;
Stelte-Ludwig, Beatrix ;
Mayer-Bartschmid, Anke ;
Unterschemmann, Kerstin ;
Bruder, Sandra ;
Linden, Lars ;
Harrenga, Axel ;
Hauff, Peter ;
Scholle, Frank-Detlef ;
Mueller-Tiemann, Beate ;
Kreft, Bertolt ;
Ziegelbauer, Karl .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) :1537-1548
[6]   Prospects and progress of antibody-drug conjugates in solid tumor therapies [J].
Govindan, Serengulam V. ;
Sharkey, Robert M. ;
Goldenberg, David M. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (07) :883-893
[7]   Targeted cancer therapy - Are the days of systemic chemotherapy numbered? [J].
Joo, Won Duk ;
Visintin, Irene ;
Mor, Gil .
MATURITAS, 2013, 76 (04) :308-314
[8]   Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy [J].
Khera, Eshita ;
Cilliers, Cornelius ;
Bhatnagar, Sumit ;
Thurber, Greg M. .
MOLECULAR SYSTEMS DESIGN & ENGINEERING, 2018, 3 (01) :73-88
[9]  
Kittaneh Muaiad, 2013, Biomark Cancer, V5, P61, DOI 10.4137/BIC.S9455
[10]   Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen [J].
Kovtun, YV ;
Audette, CA ;
Ye, YM ;
Xie, HS ;
Ruberti, MF ;
Phinney, SJ ;
Leece, BA ;
Chittenden, T ;
Blättler, WA ;
Goldmacher, VS .
CANCER RESEARCH, 2006, 66 (06) :3214-3221